FCM
ALNY icon

Fieldview Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fieldview Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Sell
1,745
-3,530
-67% -$1.06M 0.15% 225
2026
Q1 		$1.75M Buy
+5,275
New +$1.8M 0.51% 38
2025
Q4 		– Sell
-12,658
Closed -$5.77M – 480
2025
Q3 		$5.77M Buy
+12,658
New +$5.15M 0.94% 7

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldview Capital Management's ALNY Position: Q2 2026 in Review

Fieldview Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, selling an estimated $1.06M and leaving 1,745 shares worth $525K. The position accounts for 0.15% of the portfolio, ranked #225.

Fieldview Capital Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.77M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fieldview Capital Management held 1,745 shares of Alnylam Pharmaceuticals worth $525K as of Q2 2026.
  • Fieldview Capital Management sold 3,530 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
  • Alnylam Pharmaceuticals made up 0.15% of Fieldview Capital Management's portfolio in Q2 2026, its #225 holding.
  • Fieldview Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Fieldview Capital Management's Alnylam Pharmaceuticals position peaked at $5.77M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.